10月20日 - ** 药物开发商Verrica Pharmaceuticals VRCA.O股价在延时交易中上涨17%至5.17美元
** 公司称其皮肤病治疗药物Ycanth获得了欧洲药品管理局的积极反馈 (link)
** 公司计划最早于 2026 年第四季度向欧盟提交该药的监管申请
** 该药已在美国和日本获批用于治疗传染性软疣，这是一种常见的病毒性皮肤感染，通过直接接触传播，主要影响儿童。
** 股价年初至今下跌了 36
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.